Questions around this news
What does Adherium's agreement with NuvoAir Medical require?
The agreement has commenced and requires NuvoAir Medical to purchase a minimum of 1,000 next-generation inhaler sensors. The release describes the deal as part of Adherium's U.S. commercial expansion, but does not provide further details about the agreement's duration or purchase schedule.
What information can the next-generation inhaler sensors capture?
The release says the sensors can capture physiological data, including inhalation flow rate and inhalation duration, in addition to monitoring medication adherence. Adherium says these functions are intended to support people with asthma and COPD in using their medication and managing their conditions.
What does FDA 510(k) clearance mean?
A 510(k) is a U.S. Food and Drug Administration process through which a device maker demonstrates that a new medical device is substantially equivalent to a legally marketed device. Clearance is distinct from FDA approval through other regulatory pathways and applies to the device and its indicated uses.
What is a value-based specialty management platform?
It is a healthcare model that coordinates specialized care while emphasizing patient outcomes and the value of services delivered, rather than focusing only on the volume of appointments or procedures. Such platforms may work with clinicians, patients, and health plans to manage care for particular conditions or areas of medicine.
Melbourne, Australia, January 10, 2024 -- Adherium Limited (ASX:ADR) a leader in digital health technologies, is excited to announce an agreement with NuvoAir Medical, a value-based specialty management platform focused on cardiopulmonary conditions headquartered in Boston, Massachusetts. This agreement has now commenced, which requires NuvoAir to purchase a minimum of 1,000 next generation Hailie® Smartinhaler® sensors, marking another stride in Adherium's rapid commercial expansion strategy in the US.
Adherium's CEO, Rick Legleiter, emphasised the importance of this new customer within the context of the Company's business by commenting, "This partnership signifies another step forward in Adherium's accelerated rollout of our commercial strategy with another significant partner in the United States in addition to Allergy Partners and SENTA, showcasing the growing recognition of the value our digital technology brings to respiratory healthcare."
The advanced features of the next generation Hailie Smartinhalers focus on physiological data capture, including inhalation flow rate and inhalation duration alongside medication adherence monitoring. This is an important step in assisting asthma and COPD sufferers with increased support with their medication usage and disease management. Hailie is the only US FDA 510(k) cleared, drug-agnostic digital Smartinhaler available today providing insights on patient inhaler technique.
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
At a glance
- Company
- Adherium Limited
- Ticker
- ASX: ADR
- Announcement
- Partnership
- Location
- Melbourne, Australia
Key figures
- Minimum sensor purchase
- 1,000
People
- Rick LegleiterCEO
